Reimbursement for JW Pharmaceutical’s high-dose iron injection ‘Ferinject Inj’ is imminent in Korea. Although the company failed to pass the pricing negotiation stage once in 2020, analysts are seeing a true possibility for its reimbursement this time, as the company's willingness for its reimbursement is stronger than ever.

According to industry sources on the 4th, the reimbursement application for Ferinject passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee meeting in January and is currently in the drug pricing negotiation stage with the National